Circulating Extracellular Vesicles in the Pathogenesis of Type 1 Diabetes
循环细胞外囊泡在 1 型糖尿病发病机制中的作用
基本信息
- 批准号:10298747
- 负责人:
- 金额:$ 48.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-24 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:18 year oldAddressAgeAlpha CellAutoantibodiesAutoantigensAutoimmune DiseasesAutoimmunityBeta CellBiological MarkersCell DeathCell physiologyCessation of lifeCharacteristicsChildhoodCodeDataDiabetes MellitusDiagnosisDiseaseDisease ProgressionEthnic OriginEventFemaleFunctional disorderGlucagonGoalsHealthHumanHyperglycemiaInbred NOD MiceInsulin-Dependent Diabetes MellitusKnowledgeMediatingMediator of activation proteinMicroRNAsMitochondriaModelingMolecularMusNon obeseNon-Insulin-Dependent Diabetes MellitusPathogenesisPathologyPatientsPlasmaPlayRNAResearchResistanceRiskRodent ModelRoleSecondary toSevere Combined ImmunodeficiencyTestingTherapeuticUntranslated RNAclinical biomarkersclinically relevantcytotoxiccytotoxicitydiabetes controldiabeticdifferential expressiondisease diagnosisdisorder controlearly detection biomarkersextracellular vesiclesfunctional lossin vivoinsightinsulin dependent diabetes mellitus onsetinsulin secretionisletnon-diabeticnovelsexsignature moleculeuptake
项目摘要
SUMMARY: Circulating Extracellular Vesicles in the Pathogenesis of Type 1 Diabetes
Type 1 diabetes (T1D) is an autoimmune disease, characterized by death, dedifferentiation or dysfunction of
functional beta cells. However, precise molecular events that initiate beta cell loss and dysfunction or mediate
autoimmunity is a major gap in knowledge that remains unaddressed. Emerging evidence suggests that circulating
extracellular vesicles (EVs), known mediators of intercellular microcommunication, may play important roles in the
pathogenesis of T1D. However, their precise function and molecular contents, especially in the initiation of beta
cell loss and dysfunction in humans are largely undefined.
Here, we hypothesize that circulating EVs in T1D, through their distinct molecular characteristics, are
cytotoxic to beta cell health, thus contributing to the pathogenesis of T1D, with the potential to serve as
biomarkers for early disease diagnosis. Our preliminary data suggests that EVs, but not EV-depleted fraction
in the humoral factors in T1D are cytotoxic, particularly to human beta cells, but not to alpha cells. Specifically,
EVs from T1D subjects, but not from control subjects, induce human beta cell death suggesting that circulating
T1D-EVs are key components contributing to humoral cytotoxicity. Therefore, characterizing T1D EVs at various
stages of the disease and control could identify important biomarkers for early detection of the disease that
correlate with beta cell loss and dysfunction. Our research plan has the following Specific Aims:
AIM 1: To determine the functional effects of circulating EVs from pre-disease to late stage T1D subjects
on human beta and alpha cell health. We will characterize circulating EVs from the plasma of T1D subjects at
i) early (1-5 years), ii) late (>10 year) and iii) pediatric (<18 year) stages and compare them with i) autoantibody
positive non-T1D, ii) T2D (control for secondary effects such as hyperglycemia) and iii) appropriate age, ethnicity,
and sex-matched healthy control non-diabetic subjects for their effect on human beta and alpha cell health.
AIM 2: To establish the functional role of circulating EVs in the pathogenesis of T1D in vivo using a rodent
model. To provide proof-of-concept, we will administer circulating EVs from diabetic female NOD mice to non-
diabetic controls and test T1D disease progression in the recipient (Aim2A); we will inhibit EV secretion in young
pre-T1D female NOD mice and test T1D disease progression and quantify beta cell death and function (Aim2B).
AIM 3: Investigate the molecular mechanisms, cargo composition and cargo function of human T1D-
EVs. We will address the differential function of T1D EVs in beta cell cytotoxicity by investigating their uptake
mechanisms, (Aim3A); compare EV cargo in T1D and control subjects (Aim3B); examine the function of
differentially expressed EV-RNAs (Aim3C).
Our proposed research is clinically relevant and will profoundly change our understanding of the progression of
T1D. If successful, our study has the potential to identify new biomarkers and therapeutics for T1D.
摘要:循环细胞外囊泡在1型糖尿病发病机制中的作用
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Susmita Sahoo其他文献
Susmita Sahoo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Susmita Sahoo', 18)}}的其他基金
Circulating Extracellular Vesicles in the Pathogenesis of Type 1 Diabetes
循环细胞外囊泡在 1 型糖尿病发病机制中的作用
- 批准号:
10475159 - 财政年份:2021
- 资助金额:
$ 48.06万 - 项目类别:
Circulating Extracellular Vesicles in the Pathogenesis of Type 1 Diabetes
循环细胞外囊泡在 1 型糖尿病发病机制中的作用
- 批准号:
10628007 - 财政年份:2021
- 资助金额:
$ 48.06万 - 项目类别:
AAV-Exosomes: Escaping Neutralizing Antibody and Enhancing Delivery
AAV-外泌体:逃避中和抗体并增强递送
- 批准号:
10210297 - 财政年份:2019
- 资助金额:
$ 48.06万 - 项目类别:
AAV-Exosomes: Escaping Neutralizing Antibody and Enhancing Delivery
AAV-外泌体:逃避中和抗体并增强递送
- 批准号:
10428364 - 财政年份:2019
- 资助金额:
$ 48.06万 - 项目类别:
AAV-Exosomes: Escaping Neutralizing Antibody and Enhancing Delivery
AAV-外泌体:逃避中和抗体并增强递送
- 批准号:
9811209 - 财政年份:2019
- 资助金额:
$ 48.06万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 48.06万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 48.06万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 48.06万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 48.06万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 48.06万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 48.06万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 48.06万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 48.06万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 48.06万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 48.06万 - 项目类别:
Research Grant














{{item.name}}会员




